Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The chromatin and single-cell transcriptional landscapes of CD4 T cells in inflammatory bowel disease link risk loci with a proinflammatory Th17 cell population. | Front Immunol | 2023 | 37600767 | PubTator, text mining | PubMed |
| Comprehensive characterization of pyroptosis phenotypes with distinct tumor immune profiles in gastric cancer to aid immunotherapy. | Aging (Albany NY) | 2023 | 37595258 | PubTator, text mining | PubMed |
| CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor. | BMC Med Genomics | 2023 | 37592341 | PubTator, text mining | PubMed |
| Yolk sac cell atlas reveals multiorgan functions during human early development. | Science | 2023 | 37590359 | PubTator, text mining | PubMed |
| Hepatocellular carcinoma cell differentiation trajectory predicts immunotherapy, potential therapeutic drugs, and prognosis of patients. | Open Life Sci | 2023 | 37589009 | PubTator, text mining | PubMed |
| Identification of lysosomal genes associated with prognosis in lung adenocarcinoma. | Transl Lung Cancer Res | 2023 | 37577321 | PubTator, text mining | PubMed |
| BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy. | Front Oncol | 2023 | 37576888 | PubTator, text mining | PubMed |
| FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. | Front Immunol | 2023 | 37575254 | PubTator, text mining | PubMed |
| Significance of Th17 and Treg in Treatment Efficacy and Outcome in Pediatric Acute Lymphoblastic Leukemia. | Int J Mol Sci | 2023 | 37569699 | PubTator, text mining | PubMed |
| Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis. | Clin Exp Immunol | 2023 | 37565620 | PubTator, text mining | PubMed |
| Complementarity-determining region clustering may cause CAR-T cell dysfunction. | Nat Commun | 2023 | 37563127 | PubTator, text mining | PubMed |
| Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4. | Biomed Rep | 2023 | 37560313 | PubTator, text mining | PubMed |
| Identification of the novel FOXP3-dependent Treg cell transcription factor MEOX1 by high-dimensional analysis of human CD4+ T cells. | Front Immunol | 2023 | 37559728 | PubTator, text mining | PubMed |
| Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes. | Discov Oncol | 2023 | 37555866 | PubTator, text mining | PubMed |
| Construction of a two-gene prognostic model related to ferroptosis in renal cell carcinoma. | Transl Androl Urol | 2023 | 37554538 | PubTator, text mining | PubMed |
| T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. | NPJ Genom Med | 2023 | 37553332 | PubTator, text mining | PubMed |
| Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment. | Cancer Discov | 2023 | 37548431 | PubTator, text mining | PubMed |
| Immune gene signatures as prognostic criteria for cancer patients. | Ther Adv Med Oncol | 2023 | 37547445 | PubTator, text mining | PubMed |
| Identification and validation of a genetic risk signature associated with prognosis in clear-cell renal cell carcinoma patients. | Medicine (Baltimore) | 2023 | 37543772 | PubTator, text mining | PubMed |
| Advances in radiotherapy and immunity in hepatocellular carcinoma. | J Transl Med | 2023 | 37542324 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=22